Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients
Jacopo Canzian(Humanitas University), Alberto Zambelli, C. Benvenuti, Rita De Sanctis(Humanitas University), Mariangela Gaudio(Humanitas University), Riccardo Gerosa(Humanitas University), Damiano Gentile(Humanitas University), Flavia Jacobs(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Saltalamacchia, Rosalba Torrisi(IRCCS Humanitas Research Hospital), Corrado Tinterri(Humanitas University), Giovanna Masci(Humanitas University)
Cited by 1
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer
|Cancer Discovery|2020|183
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178